Board membersBDA Board The BDA board members are distinguished and experienced pre-clinical and clinical investigators who are devoted to the development of biological therapeutics: They have experience in: giving advice on or reviewing drug development strategies in pre-clinical and early clinical development designing phase I/IIl clinical trials using novel designs and endpoints to speed up and optimise the overall drug development programmes, and to avoid suboptimal drug development strategies. BDA members are involved in numerous pre-clinical and clinical studies and drug development programmes. Many are members of advisory committees within multinational pharmaceutical and biotechnology companies.
The BDA regularly takes part in meetings with other academic and research groups, e.g. National Cancer Institute (NCI), Cancer Research UK (CRUK), European Organisation for Research and Treatment of Cancer (EORTC), Central European Cooperative Oncology Group (CECOG), European Association for Cancer Research (EACR), American Association for Cancer Research (AACR), German Society of Hematology and Oncology and others.
The Board members are:
"The future of molecular targeted therapy requires a detailed understanding of translational R&D and economics."
